Cogent Biosciences, Inc.

Contributing Author

Recent Articles by Cogent Biosciences, Inc.

14 hours	Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting COGT GlobeNewswire
Apr-17	Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 COGT GlobeNewswire
Apr-01	Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) COGT -8.44% GlobeNewswire
Mar-16	Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) COGT GlobeNewswire
Feb-28	Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting COGT GlobeNewswire
Feb-17	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results COGT GlobeNewswire
Feb-10	Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting COGT GlobeNewswire
Jan-26	Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) COGT GlobeNewswire
Jan-20	Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) COGT GlobeNewswire
Jan-12	Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio COGT GlobeNewswire
Jan-06	Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference COGT GlobeNewswire
Dec-30	Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis COGT GlobeNewswire
Dec-08	Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) COGT GlobeNewswire
Dec-06	Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) COGT GlobeNewswire
Nov-14	Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference COGT GlobeNewswire
Nov-11	Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031 COGT +5.51% GlobeNewswire
Nov-10	Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock COGT +119.03% GlobeNewswire
Nov-10	Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST) COGT +119.03% GlobeNewswire
Nov-03	Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results COGT GlobeNewswire
Nov-03	Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting COGT GlobeNewswire
Oct-24	Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics COGT +7.07% COGT GlobeNewswire
Oct-20	Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib COGT GlobeNewswire
Sep-29	Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) COGT GlobeNewswire
Aug-26	Cogent Biosciences Announces Participation in the Citi Biopharma Conference COGT GlobeNewswire
Aug-05	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results COGT -5.73% GlobeNewswire
Jul-10	Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares COGT GlobeNewswire
Jul-08	Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock COGT +6.34% GlobeNewswire
Jul-08	Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock COGT +6.34% COGT GlobeNewswire
Jul-07	Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis COGT +23.35% GlobeNewswire
Jun-11	Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing COGT GlobeNewswire
May-29	Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference COGT +12.91% GlobeNewswire
May-06	Cogent Biosciences Reports First Quarter 2025 Financial Results COGT -15.62% GlobeNewswire

Cogent Biosciences, Inc.

Recent Articles by Cogent Biosciences, Inc.

Upgrade your Finviz experience